Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Topotecan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Topotecan. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2006-002074-22 Sponsor Protocol Number: UM2005/00201/00 Start Date*: 2006-10-18
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Phase III, Open-Label Study of Oral Topotecan Plus Whole-Brain Radiation Therapy (WBRT) Compared with WBRT Alone in Patients with Brain Metastases from Non-Small Cell Lung Cancer.
    Medical condition: Brain metastases from primary non-small cell lung cancer (NSCLC).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2016-003726-17 Sponsor Protocol Number: M16-289 Start Date*: 2017-06-27
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have Firs...
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) PT (Completed) GB (Completed) CZ (Completed) DE (Completed) HU (Completed) BE (Completed) LV (Completed) NL (Completed) GR (Completed) BG (Completed) PL (Completed) FR (Completed) ES (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2009-017054-12 Sponsor Protocol Number: 1775-008 Start Date*: 2010-05-20
    Sponsor Name:Merck & Co., Inc.
    Full Title: A Two Part, Phase I-IIa Study Evaluating MK-1775 in Combination With Topotecan/Cisplatin in Adult Patients With Cervical Cancer
    Medical condition: Patients with advanced, metastatic, and recurrent carcinoma of the uterine cervix
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008229 Cervical cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-004471-13 Sponsor Protocol Number: PM1183-C-008-21 Start Date*: 2022-08-03
    Sponsor Name:Pharma Mar, S.A.
    Full Title: A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination with Irinotecan versus Investigator’s Choice (Topotecan or Irinotecan) in Relaps...
    Medical condition: Small Cell Lung Cancer (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BG (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001559-39 Sponsor Protocol Number: 01/2005_01 Start Date*: Information not available in EudraCT
    Sponsor Name:Charité-Campus Mitte und Campus Virchow-Klinikum
    Full Title: Randomisierte Phase II Studie zum Vergleich einer wöchentlichen Topotecangabe mit der Topotecangabe an fünf aufeinander folgenden Tagen bei Patientinnen mit platinresistentem rezidiviertem epitheli...
    Medical condition: Patientinnen mit Ovarialkarzinom und Rezidiv / Progress < 6 Monate nach Ende der Primärtherapie mit Platin und Taxan
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-000349-20 Sponsor Protocol Number: IFG-01-0106 Start Date*: 2006-10-11
    Sponsor Name:Institut fuer Frauengesundheit GmbH
    Full Title: Prospective Randomized Phase-III-Trial of Paclitaxel plus Topotecan versus Topotecan plus Cisplatin in Recurrent or Persistent Cervical Carcinoma
    Medical condition: Chemotherapeutical treatment of patients with recurrent or persistent or metastatic cervical carcinoma stage IVb
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004231-25 Sponsor Protocol Number: MS201923_0050 Start Date*: 2024-05-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer
    Medical condition: Relapsed platinum resistant small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2015-001097-18 Sponsor Protocol Number: CA209-331 Start Date*: 2015-09-15
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects with Relapsed Small-cell Lung Cancer after Platinumbased First Line Chemotherapy
    Medical condition: Relapsed Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041069 Small cell lung cancer limited stage PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041070 Small cell lung cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) AT (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) HU (Completed) GR (Completed) PL (Completed) ES (Completed) FR (Completed) RO (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002089-13 Sponsor Protocol Number: NB 2006 xx Start Date*: 2006-05-26
    Sponsor Name:University Hospitals of Leicester NHS Trust
    Full Title: International Phase II Studies of 131I-mIBG in combination with topotecan and peripheral blood stem cell rescue for (A) primary resistant high risk neuroblastoma and (B) relapsed stage 4 neuroblast...
    Medical condition: Neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004084-66 Sponsor Protocol Number: om 112 Start Date*: 2002-07-09
    Sponsor Name:OSPEDALE ONCOLOGICO DI BARI
    Full Title: A phase II study on the efficacy and safety of topotecan in the treatment of patients with brain metastases
    Medical condition: Brain metastases
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061287 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011922-33 Sponsor Protocol Number: TRIAS2009 Start Date*: 2009-11-24
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A randomized, double-blind, placebo controlled, multicenter Phase II study to assess the efficacy and safety of Sorafenib added to standard treatment with Topotecan in patients with platinum-resist...
    Medical condition: This study is a prospective, randomized, double-blind, multi-center placebo-controlled phase II study in order to determine progression-free survival of patients with platinum-resistant or refract...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004611-13 Sponsor Protocol Number: G1T28-03 Start Date*: 2017-03-16
    Sponsor Name:G1 Therapeutics
    Full Title: Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy
    Medical condition: Extensive-Stage Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) SI (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000259-17 Sponsor Protocol Number: PazTo_2010 Start Date*: 2012-04-20
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A phase I/II study of Pazopanib and weekly Topotecan in patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer
    Medical condition: This study is a prospective single-arm, open-label, multicenter phase I/II trial. The phase I-trial is a dose-escalation trial to determine the maxium tolerated dose (MTD) of pazopanib in combinati...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-006069-34 Sponsor Protocol Number: 1564 Start Date*: Information not available in EudraCT
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: Clinical efficacy and cell mobilization activity of pegfilgrastim in patients with gynaecological malignancies in therapy with topotecan.
    Medical condition: ovarian cancer, cervical cancer, endometrial cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038594 Reproductive neoplasms female malignant and unspecified HLGT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001069-14 Sponsor Protocol Number: ABC-2007-SCLC-02 Start Date*: 2008-02-15
    Sponsor Name:Aktion Bronchialkarzinom e.V.
    Full Title: A phase II open-label, multi-centre, randomised, prospective, parallel-group study comparing Topotecan/Carboplatin administered 5 days versus 3 days versus Topotecan monotherapy daily x 5 as second...
    Medical condition: Prospective randomized multi-center open label phase II study to determine the antitumoral activity and the feasibility of a combination therapy with Hycamtin/Carboplatin administered 5-days versus...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041068 Small cell lung cancer extensive stage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015296-26 Sponsor Protocol Number: SCLC Start Date*: 2009-12-09
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: MULTICENTRIC PROSPECTIVE DOSE-FINDING AND PHASE II STUDY WITH ORAL TOPOTECAN IN ADVANCED SMALL-CELL LUNG CANCER (SCLC) PATIENTS RECURRENT AFTER A FIRST LINE THERAPY
    Medical condition: patients with ADVANCED SMALL-CELL LUNG CANCER (SCLC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041059 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002499-14 Sponsor Protocol Number: GENOM-04M1/05 Start Date*: 2005-09-15
    Sponsor Name:Grupo Español de Neurooncología Médica (GENOM)
    Full Title: "Protocolo fase II de tratamiento con Topotecan e irradiación holocraneal en metástasis cerebrales".
    Medical condition: Pacientes adultos con metástasis cerebrales.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005176-28 Sponsor Protocol Number: TOPOCIS Start Date*: 2008-11-07
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: A PROSPECTIVE PHASE II MULTICENTRIC STUDY OF WEEKLY TOPOTECAN AND CISPLATIN (TOPOCIS) AS NEOADJUVANT TREATMENT IN PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CERVICAL CANCER
    Medical condition: Locally advanced cervical carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002189-64 Sponsor Protocol Number: ALDOXORUBICIN-P2-SCLC-01 Start Date*: 2014-11-04
    Sponsor Name:CytRx Corporation
    Full Title: A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects with Metastatic Small Cell Lung Cancer Who Either Rela...
    Medical condition: Metastatic Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003989-18 Sponsor Protocol Number: AMR PH GL 2007 CL 001 Start Date*: 2008-04-24
    Sponsor Name:Celgene Corporation
    Full Title: A Randomized, Open-Label, Multinational Phase 3 Trial Comparing Amrubicin Versus Topotecan in Patients With Extensive or Limited and Sensitive or Refractory Small Cell Lung Cancer After Failure of ...
    Medical condition: Extensive or limited and sensitive or refractory SCLC after failure of first-line chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041071 Small cell lung cancer stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) DE (Completed) DK (Completed) HU (Completed) NL (Completed) AT (Completed) CZ (Completed) IT (Completed) FR (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 22:35:54 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA